Skip to content

Medical-device intelligence

NYI: Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer

FDA product code NYI: Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer. View classification details, related manufacturers, 510(k) clearances, and recall records.

FDA classification ↗

Classification details

Product code
NYI
FDA device name
Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer
Device class
2
Regulation number
866.6040
Medical specialty
Immunology
Review panel
PA

FDA definition

A device which uses a gene expression profile of a breast cancer tumor, from patients stage i or stage ii lymph node negative, with a tumor size of <5.0 cm, to provide a risk assessment for distant recurrence of breast cancer. The result is indicated for use only as a prognostic marker by physicians along with a number of other factors to assess the risk of recurrence of breast cancer.
Explore immunology records →
A product code groups records by FDA classification. It does not establish identical intended uses, commercial availability, or comparative device safety.

Record activity in this scope

9 clearance records and 1 recall records in the covered releases, across 5 source company names and 1 product codes. Dated history runs from Jun 22, 2007 to Sep 8, 2022.

Monthly counts through October 2026
Month510(k) decisionsRecall initiations
October 202500
November 202500
December 202500
January 202600
February 202600
March 202600
April 202600
May 202600
June 202600
July 202600
August 202600
September 202600
October 202600

Product codes represented

All-history totals use the covered releases; monthly counts stop at the last calendar month covered by both sources. Clearances use decision dates; recalls use initiation dates. 0 records lack the required date and are excluded from monthly counts. These are records, not product launches, market share, incidence rates, or comparative safety. Feed filters below do not change this overview.

Clearances and recall records

10 matching records
Device / recordCompany in FDA recordSourceSource date
MammaPrint FFPE NGS KitK210973 · NYIAgendia, Inc.510(k)Sep 8, 2022FDA decision date
MammaPrintK201902 · NYIAgendia, Inc.510(k)Nov 5, 2020FDA decision date
MAMMAPRINT FFPEK141142 · NYIAgendia510(k)Jan 23, 2015FDA decision date
PROSIGNA BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAYK141771 · NYINanostring Technologies, Inc.510(k)Nov 7, 2014FDA decision date
PROSIGNA(TM) BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAYK130010 · NYINanostring Technologies510(k)Sep 6, 2013FDA decision date
MAMMAPRINTK101454 · NYIAgendia510(k)Jan 28, 2011FDA decision date
Agendia MammaPrint, Catalog Numbers MP01, MP US version 03Z-1321-2010 · NYIAgendia IncRecallApr 12, 2010FDA classification date
MODIFICATION TO MAMMAPRINTK081092 · NYIAgendia510(k)Dec 11, 2009FDA decision date
MODIFICATION TO MAMMAPRINTK080252 · NYIAgendia BV510(k)Jul 21, 2008FDA decision date
MAMMAPRINTK070675 · NYIAgendia BV510(k)Jun 22, 2007FDA decision date

Manufacturers in these records

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 21, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 21, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 21, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗